Serpin family A member 1 is an oncogene in glioma and its translation is enhanced by NAD(P)H quinone dehydrogenase 1 through RNA-binding activity

Wenjun Liu; Min Du; Hongping Wan; Hao Yang; Xiaorong Deng; Yu Chen; Qian Zhang

doi:10.1515/med-2022-0572

Artikel Open Access

Serpin family A member 1 is an oncogene in glioma and its translation is enhanced by NAD(P)H quinone dehydrogenase 1 through RNA-binding activity

Wenjun Liu , Min Du , Hongping Wan , Hao Yang , Xiaorong Deng , Yu Chen und Qian Zhang

Veröffentlicht/Copyright: 20. Oktober 2022

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Open Medicine Band 17 Heft 1

Abstract

Serpin family A member 1 (SERPINA1) is expressed abundantly in gliomas and can predict unfavorable prognosis of patients with glioma. Studies have shown that nicotinamide adenine dinucleotide phosphate quinone dehydrogenase 1 (NQO1) can promote the proliferation of glioblastoma multiforme cells and enhance the expression of SERPINA1, but its effects on glioma cells remain unknown. In this study, we explored the functions of SERPINA1 in glioma tumorigenesis in vitro and then investigated whether NQO1 affects the protein expression of SERPINA1 and its mRNA level. The results showed that the translation of SERPINA1 was suppressed while its mRNA level had no significant changes under the condition of NQO1 silencing. Luciferase reporter assay and biotin pull-down assay further indicated that NQO1 bond with SERPINA1 3′ untranslated region. miR-1321 was also identified to target SERPINA1, repressing its mRNA and protein levels. SERPINA1 and NQO1 promoted glioma cell proliferation and suppressed cell apoptosis. Moreover, SERPINA1 rescued the effects of sh-NQO1 in glioma cell malignant phenotypes. In conclusion, our findings showed that oncogene NQO1 and antioncogene miR-1321 bind to oncogene SERPINA1 to affect proliferation and apoptosis of glioma cells, which can bring new solution of antitumor treatments for glioma in the future.

Keywords: glioma; SERPINA1 ; NQO1 ; RNA-binding protein; miR-1321

1 Introduction

Glioma, known as an aggressive malignant cancer in brain, causes nearly 80% of malignant brain cancers in the world with a high rate of relapse [1,2,3]. It is characterized by infiltrative growth of malignant glioma cells into the surrounding brain parenchyma, which makes it hard for operative treatment. Although treatment for neuronal oncology has been improved rapidly, the prognosis of glioma is unsatisfactory [4]. Novel treatment strategies for malignant gliomas should focus on improving tumor debulking and enhancing tumor cell killing [5]. Glioblastoma multiforme (GBM) is a highly immunosuppressive tumor, and immunotherapy can achieve long-lasting tumor remission by manipulating the immune system [6]. However, immunotherapy may cause over-inflammation, and its efficacy is not high [7]. Therefore, it is important to develop new strategies for the treatment of glioma.

Serpin family A member 1 (SERPINA1), identified in 1981 [8], serves as a serine protease inhibitor gene. It was reported that in patients with carcinomas, SERPINA1 enhances the invasive and metastatic abilities of carcinomas in gastric cancer, colorectal carcinoma, and lung cancer [9,10,11,12,13] and indicates poor prognosis of patients with colorectal cancer [14]. The expression of SERPINA1 was found in the spindle cells and pleomorphic cells from the sarcomatous area of GBM [15,16]. An immunostaining result demonstrates the expression of SERPINA1 in gliomas [17]. In this study, we used short hairpin RNAs (shRNAs) to determine the effects of SERPINA1 on the proliferation and apoptosis of glioma cells.

Nicotinamide adenine dinucleotide phosphate quinone oxidoreductase (NQO1), one of the major cytosolic quinone reductases, induces a two-electron reduction of quinones substrate to hydroquinones. Previous studies showed that NQO1 increases glioma cell proliferation [18,19]. Meanwhile, new evidence suggested that the expression of SERPINA1 is upregulated by NQO1 through RNA-binding activity [20]. However, the property of the binding of NQO1 to SERPINA1 in glioma cells remains unknown.

We made a hypothesis that NQO1 binds to SERPINA1 to play an oncogenic role in glioma cells. A noncoding RNA miR-1321 targeting SERPINA1 was subsequently investigated. Influences of NQO1, SERPINA1, and miR-1321 on the proliferation and apoptosis of glioma cells were assessed.

2 Methods and materials

2.1 Bioinformatics analysis

Interactive Analysis of Gene Expression Profiles, abbreviated as GEPIA (http://gepia.cancer-pku.cn/), is a web server to analyze the expression of SERPINA1 in glioma and normal tissues from the TCGA and GTEx projects. Association of NQO1 and SERPINA1 with the prognosis of glioma patients as well as the expression correlation between NQO1 and SERPINA1 in glioma tissues were also obtained from GEPIA.

2.2 Cell culture

The normal human astrocyte (NHA) (Cloneticss Astrocyte Cell Systems, Cambrex BioScience, Wokingham, UK) and four glioma cell lines (U251, T98G, LN-229, and A172) (Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China) were used. The GBM cells were first stored in 5% CO₂ at 37°C in a humidified chamber and then cultured with 10% fetal bovine serum [21]. DMEM supplemented with 100 units/mL penicillin, 100 μg/mL streptomycin, and 2 mM Glutamax (Invitrogen) was used to culture cells under standard cell culture conditions. Primary glioma cells were purchased from PriCells (HUM-TUM-0018, Wuhan, China) and cultured in special basal medium for primary glial cells (MED-0014, PriCells) supplemented with PBS and antibiotics.

2.3 Cell transfection

A SERPINA1 complementary DNA (cDNA) was cloned into the pcDNA3.1 vector (Genechem, Shanghai, China) to produce the SERPINA1 overexpressing vector. The shRNAs used for targeting SERPINA1 and NQO1 were synthesized by Genechem. MiR-1321 inhibitor for silencing miR-1321 expression and miR-1321 mimics for enhancing miR-1321 expression were synthesized by GenePharma (Shanghai, China). Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used for the transfection of abovementioned oligonucleotides or vectors into T98G and A172 cells for 24 h.

2.4 Colony formation assay

Cells were plated in six-well plates (1,000 cells per well) for cell culture for 2 weeks. Next, 75% alcohol and 1% crystal violet were used to fix and stain the colonies.

2.5 Flow cytometry

The evaluation of apoptosis was taken using flow cytometry with Annexin V (PE)/7AAD (BD Biosciences, San, Jose, CA, USA) double staining. Annexin V/7AAD solution was used to incubate cells for 15 min at room temperature in the dark after transfection. A FACSCanto™ system (BD Biosciences) was used to analyze the samples. Annexin V and 7AAD positive cells were late apoptotic cells. Annexin V positive and 7AAD-negative cells were early apoptotic cells. Apoptotic rate was calculated as the percentage of early apoptotic cells + percentage of late apoptotic cells.

2.6 RNA isolation and RT-qPCR analysis

TRIzol was used to isolate RNA from cell extracts according to manufacturer’s procedures. An iScript™ Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad) was used for reverse transcription. iTaq™ Universal SYBR® Green Supermix (Bio-Rad) was used for real-time quantitative (q)PCR analysis. GAPDH was used as a reference gene. The primer used for amplification are listed as the following:

SERPINA1: F: 5′-ATCATAGGCACCTTCACGG-3′; R: 5′-TCTTTAAAGGCAAATGGGAGAG-3′.

NQO1: F: 5′-ACATCACAGGTAAACTGAAGG-3′; R: 5′-TCAGATGGCCTTCTTTATAAGC-3′.

GAPDH: F: 5′-TCAAGATCATCAGCAATGCC-3′; R: 5′-CGATACCAAAGTTGTCATGGA-3′.

2.7 Luciferase reporter assay

The psiCHECK2 Luciferase reporter vector (Promega, Madison, WI, USA) was used to load the 3′-UTR, coding regions, and 5′-UTR of SERPINA1. A172 and T98G cells were seeded into 24-well plates. Then, sh-DQO1 plasmid and luciferase reporter vectors were co-transfected into the cells for 24 h using the Effectene transfection reagent (Qiagen, Hilden, Germany). After that, a Dual-Luciferase assay system (Promega, Madison, WI, USA) was used to measure the Firefly luciferase (FL) activity and Renilla luciferase (RL) activity. The results were shown as the normalized value of FL to RL.

2.8 Immunofluorescence staining

Four percent paraformaldehyde was used to fix cells for 30 min. Five percent blocking solution was used for permeabilization. An anti-SERPINA1 antibody (ab207303, 1:1,000; Abcam, Cambridge, UK) was used to incubate cells overnight at 4°C followed by washing with phosphate-buffered saline. A goat anti-rabbit IgG Alexa Fluor® 647 antibody (ab150075, 1:1,000; Abcam) was used as second antibody and used to incubate the membrane for 2 h. 4′,6-Diamidino-2-phenylindole (DAPI) was used to counterstain cell nuclei. At last, a fluorescence microscope (IX71, Olympus Corporation, Tokyo, Japan) was used to capture images.

2.9 Western blot

RIPA buffer was used to prepare whole-cell lysates. Five micrograms of proteins were isolated with 4–15% Criterion™ TGX™ precast gels (Bio-Rad) by electrophoresis and transferred to nitrocellulose membrane using Trans-Blot Turbo™ Transfer System (Bio-Rad). After that, primary antibodies against NQO1 (ab80588, 1:10,000; Abcam), SERPINA1 (ab207303, 1:5,000; Abcam), and GAPDH (ab8245, 1:1,000, Abcam) were added for incubation overnight at 4°C. Next, appropriate HRP-labeled secondary antibody IgG (ab7090, 1:1,000; Abcam) was added. Enhanced chemiluminescence (Amersham) was used to detect immunocomplexes. At last, quantitative densitometry of the protein bands was performed with the ImageJ software (National Institutes of Health).

2.10 Biotin pull-down assay

Primers containing the T7 RNA polymerase promoter sequence were used as templates for PCR. In vitro transcription was performed with a MegaScript T7 kit (Ambion). Purification was taken using Nuc-Away Spin Columns (Applied Biosystems). Cytoplasmic lysates from A172 and T98G cells (150 μg lysate, 1 μg biotinylated RNA) were incubated with biotinylated transcripts for 30 min at room temperature. Streptavidin-coated magnetic Dynabeads (Dynal) were used to isolate complexes. NQO1 protein was detected by western blot. The primer used to prepare biotinylated SERPINA1 3′UTR is listed as follows: forward, 5′-AGTAATACGACTCACTATAGGGCCCAGAACTGCCTGATCGTG-3′; reverse, 5′-GCCATTCCTGGTAGAGACGG-3′.

2.11 Statistical analysis

Statistical differences were determined by unpaired Student’s t test between two groups or one-way analysis of variance (ANOVA) among three or more groups. GraphPad Prism 6.0 was used to generate p values (p < 0.05 indicates significance). Error bar represents standard error of the mean (SEM).

3 Results

3.1 SERPINA1 is Upregulated in Glioma

Using the GEPIA dataset, we obtained SERPINA1 expression in glioma tumors and normal tissues. The findings revealed that glioblastoma has higher SERPINA1 expression level than normal tissue (p < 0.05) (Figure 1a). The survival analysis suggested that glioma patients with high level of SERPINA1 expression had poor survival (Figure 1b and c). The expression of SERPINA1 at the messenger RNA (mRNA) and protein levels was also measured in NHA and four glioma cell lines, which showed that the expression of SERPINA1 was increased remarkably in glioma cells (Figure 1d and e). Higher expression of SERPINA1 in T98G and A172 cells than NHA was confirmed by immunofluorescence staining, which also indicates the cytoplastic location of SERPINA1 (Figure 1f). These results suggest that SERPINA1 might indicate poor prognosis in gliomas.

Figure 1

SERPINA1 is upregulated in glioma. (a) Differential expression of SERPINA1 in glioblastoma (box plot) (red: tumor tissue, gray: normal tissue). (b and c) Kaplan–Meier survival curves of disease-free survival and overall survival of patients who had gliomas with differential expression of SERPINA1. (d and e) qRT-PCR analysis of SERPINA1 mRNA expression and western blotting analysis of SERPINA1 protein in NHA, U251, T98G, LN-229, and A172 cell lines. One-way ANOVA was conducted. (f) Co-staining of SERPINA1 (red) with DAPI (blue) in NHA, T98G, and A172 cell lines. One-way ANOVA was conducted. Data are expressed as means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001, n = 3).

3.2 SERPINA1 affects the proliferation and apoptosis of glioma cells

The relative SERPINA1 expression was reduced with transfection of sh-SERPINA1#1/2/3 (Figure 2a) and increased significantly with transfection of pcDNA SERPINA1 (Figure 2b). Then, colony formation assay was taken to analyze the impact of SERPINA1 silence on the proliferation of glioma cells. The proliferation was significantly suppressed by sh-SERPINA1 and promoted by pcDNA SERPINA1 (Figure 2c and d). To explore whether sh-SERPINA1 inhibits cell proliferation by enhancing apoptosis, a flow cytometry assay (Annexin V/7AAD staining) was conducted. The results showed that in glioma cells, apoptosis rate was increased when SERPINA1 was silenced (Figure 2e and f). These findings showed that SERPINA1 promotes the proliferative ability of glioma cells and suppresses apoptosis.

Figure 2

SERPINA1 affects the proliferation and apoptosis of glioma cells. (a) Relative SERPINA1 mRNA expression level in T98G and A172 cells transfected with sh-SERPINA1, determined by qRT-PCR assay. One-way ANOVA was conducted. (b) Relative SERPINA1 mRNA expression level in T98G and A172 cells transfected with pcDNA SERPINA1, determined by qRT-PCR assay. Student’s t test was conducted. (c and d) Colony formation assay and its quantitative diagram. One-way ANOVA was conducted. (e) Annexin V/7AAD double staining assay and apoptosis rate in T98G. One-way ANOVA was conducted. (f) Annexin V/7AAD double staining assay and apoptosis rate in A172. One-way ANOVA was conducted. Data are expressed as means ± SEM (**p < 0.01; ***p < 0.001, n = 3).

3.3 NQO1 enhanced SERPINA1 mRNA translation through binding to the 3′UTR

The survival analysis showed that high level of NQO1 is associated with the low survival rates of glioma patients (Figure 3a). SERPINA1 expression had positive correlation with NQO1 expression in glioblastoma (Figure 3b). The relative mRNA level of NQO1 was suppressed in T98G and A172 cells after transfection with sh-NQO1 (Figure 3c). Silence of NQO1 reduced the protein expression of SERPINA1 without causing significant changes in its mRNA level (Figure 3d–e). To explore NQO1 binds to which region of SERPINA1, a luciferase reporter construct (psiCHECK2) bearing the RL coding region was used to load SERPINA1 3′UTR, coding region, and 5′UTR (Figure 3f). The silence of NQO1 obviously reduced the activity of psiCHECK2-SERPINA1-3′UTR and had no significant effects on plasmids containing SERPINA1 coding region and 5′UTR, indicating that NQO1 directly binds with SERPINA1 3′UTR (Figure 3g). Binding assays using biotinylated transcripts indicated that in both A172 and T98G lysates, NQO1 has significant interaction with the 3′UTR of SERPINA1 mRNA (Figure 3h).

Figure 3

NQO1 enhanced SERPINA1 mRNA translation through binding to the 3′UTR. (a) Kaplan–Meier survival curves of disease-free survival of patients who had gliomas with differential expression of NQO1. (b) Correlation between NQO1 and SERPINA1 expression in glioma tissues. (c) Relative NQO1 mRNA expression level in T98G and A172 cells transfected with sh-NQO1, determined by qRT-PCR assay. One-way ANOVA was conducted. (d) Relative SERPINA1 mRNA expression level in T98G and A172 cells transfected with sh-NQO1, determined by qRT-PCR assay. One-way ANOVA was conducted. (e) Relative SERPINA1 grey densities in A172 and T98G cells after transfection with sh-NQO1. One-way ANOVA was conducted. (f) 3′UTR, coding region, and 5′UTR of SERPINA1 mRNA were subcloned downstream FL coding sequence, with RL expressed from the same construct as control. (g) The ratios of FL/RL activity in glioma cells. NQO1 silencing inhibited FL/RL reporter activity in T98G and A172 cells. Student’s t test was conducted. (h) RNA pull-down assay followed by western blot revealed the existence of NQO1 protein that is pulled down by biotin-labelled SERPINA1 3′UTR. Data are expressed as means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001, n = 3).

3.4 NQO1 boosts the proliferation of glioma cells by reducing apoptosis

The colony formation ability of glioma cells was suppressed by sh-NQO1 and enhanced by pcDNA-NQO1. pcDNA-SERPINA1 rescued the effects of sh-NQO1 on cell proliferation and sh-SERPINA1 had the same rescue function on pcDNA-NQO1 (Figure 4a). Furthermore, Annexin V/7AAD staining followed by flow cytometry analysis showed that pcDNA-SERPINA1 suppressed the apoptosis rate that is promoted by sh-NQO1, whereas sh-SERPINA1 restored the declined apoptosis rate that is induced by pcDNA-NQO1 (Figure 4b). These findings suggested that NQO1 facilitates the proliferation of glioma cells by suppressing the apoptosis, which depends on the translation of SERPINA1.

Figure 4

NQO1 boosts the proliferation of glioma cells by reducing apoptosis. (a) Colony formation assay and quantitative analysis of T98G and A172 cells transfected with different plasmids (control, sh-NQO1, sh-NQO1 + pcDNA-SERPINA1, pcDNA-NQO1, pcDNA-NQO1 + sh-SERPINA1). One-way ANOVA was conducted. (b) Annexin V/7AAD double staining assay was used to show cell apoptosis rate in T98G and A172 cells. One-way ANOVA was conducted. Data are expressed as means ± SEM (***p < 0.001 vs control, ^## p < 0.01, ^### p < 0.001 vs sh-NQO1, ^&& p < 0.01, ^&&& p < 0.001 vs pcDNA-NQO1, n = 3).

3.5 NQO1 suppresses SERPINA1 translation and SERPINA1 rescues effects of sh-NQO1 on proliferation and apoptosis of primary glioma cells

sh-NQO1 did not affect SERPINA1 mRNA (Figure 5a) but decreased its protein expression in primary glioma cells (Figure 5b). Silencing of NQO1 reduced the luciferase activity of psiCHECK2-SERPINA1-3′UTR in primary glioma cells (Figure 5c). Moreover, cell proliferation and apoptosis assays were conducted using primary glioma cells. The results revealed that sh-NQO1 reduced colony number and increased cell apoptosis rate, while pcDNA-SERPINA1 had inverse effects. pcDNA-SERPINA1 rescued the effects of sh-NQO1 in the primary glioma cell proliferation and apoptosis (Figure 5d–e).

Figure 5

NQO1 binds to the 3′UTR of SERPINA1 mRNA and suppresses its translation, and SERPINA1 rescues effects of sh-NQO1 on proliferation and apoptosis of primary glioma cells. (a) Expression of SERPINA1 in sh-NQO1#1/2 transfected primary glioma cells was assessed by qRT-PCR. One-way ANOVA was conducted. (b) SERPINA1 protein levels in sh-NQO1#1/2 transfected primary glioma cells. One-way ANOVA was conducted. (c) The ratios of FL/RL activity in sh-NQO1 transfected primary glioma cells. Student’s t test was conducted. (d) Colony formation assay results and quantitative analysis of primary glioma cells after transfection with sh-NQO1, pcDNA-SERPINA1, sh-NQO1 + pcDNA-SERPINA1. One-way ANOVA was conducted. (e) Annexin V/7AAD double staining assay results and quantitative analysis of primary glioma cells after indicated transfections. One-way ANOVA was conducted. Data are expressed as means ± SEM (**p < 0.01, ***p < 0.001 vs sh-NC or control, ^### p < 0.001 vs sh-NQO1, n = 3).

3.6 miR-1321 is a negative regulator upstream SERPINA1

Using the starBase online database and under the condition of high stringency of CLIP Data and program number ≥3, miR-1321 was identified to potentially target SERPINA1 (Figure 6a). miR-1321 shows downregulated expression in glioma cells than control NHA cell line (Figure 6b). miR-1321 mimics decreased SERPINA1 protein expression, while miR-1321 inhibitor caused the upregulation of SERPINA1 protein expression (Figure 6c–d) and rescued the suppressive effect of sh-NQO1 in SERPINA1 protein expression (Figure 6e). miR-1321 inhibitor increased the expression of psiCHECK2-SERPINA1-3′UTR (Figure 6f) and rescued the inhibitory effect of sh-NQO1 on psiCHECK2-SERPINA1-3′UTR (Figure 6g). Moreover, miR-1321 inhibitor increased colony number of T98G and A172 cells and rescued the effects of sh-NQO1 in cell proliferation (Figure 6h).

Figure 6

MiR-1321 is a negative regulator upstream SERPINA1. (a) A brief flow chart shows how miR-1321 was identified as a hit. (b) miR-1321 expression in NHA, U251, T98G, LN-229, and A172 cell lines. One-way ANOVA was conducted. (c and d) SERPINA1 protein expression in T98G and A172 cells after transfection with miR-1321 mimics or inhibitor. Student’s t test was conducted. (e) SERPINA1 protein levels in T98G and A172 cells after transfection with sh-NQO1#1 or sh-NQO1#1 + miR-1321 inhibitor. One-way ANOVA was conducted. (f) The ratios of FL/RL activity of psiCHECK2-SERPINA1-3′UTR in T98G and A172 cells after transfection with miR-1321 mimics. Student’s t test was conducted. (g) Relative luciferase activity of psiCHECK2-SERPINA1-3′UTR in T98G and A172 cells after transfection with sh-NQO1#1 or sh-NQO1#1 + miR-1321 inhibitor. One-way ANOVA was conducted. (h) Colony formation assay results and quantitative analysis of T98G and A172 cells after transfection with sh-NQO1#1 or sh-NQO1#1 + miR-1321 inhibitor. One-way ANOVA was conducted. Data are expressed as means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001 vs the first group in each panel, ^# p < 0.05, ^## p < 0.01, ^### p < 0.001 vs sh-NQO1, n = 3).

4 Discussion

In the present work, we confirmed that NQO1 functions as an RNA-binding protein (RBP) that binds with SERPINA1 mRNA and enhances its translation, facilitating the proliferation of glioma cells by reducing the apoptosis. NQO1 binds with SERPINA1 mRNA and significantly increases its translation, thus boosting glioma tumorigenesis. Moreover, miR-1321 targets SERPINA1 mRNA and represses its translation. MiR-1321 exerts an opposite effect of SERPINA1. The mutual effect of miR-1321 and NQO1 on SERPINA1 will cast new direction for treatment of glioma in the future exploration.

Glioma has been known as a primary malignant carcinoma in central systema nervosum [22]. Many studies about malignant cancers focused only on gene coding proteins, and their interactions are in lack of exploration [23]. Alpha-1 antitrypsin, the protein encoded by SERPINA1, is synthesized mainly by pulmonary alveolar cells, macrophages, and hepatocytes and modulates protease and corresponding inhibitors to defend glioma cells from host offense [24]. It also inhibits the cytotoxic reactions of lymphocytes [25,26,27,28]. The high expression of SERPINA1 may protect tumor cells from enzymes and immune system [29]. We found that high expression of SERPINA1 marks poor overall survival in glioma. The results of function assays showed that SERPINA1 increased glioma cell proliferation by suppressing apoptosis.

NQO1 binds with many mRNAs including SERPINA1 [30,31]. We used shRNAs against NQO1 to analyze the effect of NQO1 silence on SERPINA1, which showed the same results as previous work that it downregulated the expression of SERPINA1 at the protein level but not the mRNA level [30,31]. Through the luciferase reporter assay, our findings suggested that NQO1 binds to the 3′UTR of SERPINA1 mRNA. Considering the pro-proliferative and anti-apoptotic effects of SERPINA1 in glioma, we had the hypothesis that by upregulating the expression of SERPINA1, NQO1 would enhance the proliferation of glioma cells and suppress apoptosis, and such hypothesis was confirmed by the rescue assays.

NQO1 may compete with the RBP suppressing SERPINA1 translation or cooperate with RBP promoting SERPINA1 translation. It is also possible that NQO1 competes with certain microRNA (miRNA) that suppresses SERPINA1 translation. In this study, we identified miR-1321 as a negative regulator upstream SERPINA1. MiR-1321 bond with SERPINA1 3′UTR and reduced its protein expression. miR-1321 inhibitor rescued the negative effect of sh-NQO1 on psiCHECK2-SERPINA1-3′UTR activity and SERPINA1 protein expression. Moreover, miR-1321 shows downregulation in glioma cells and its silencing reduced glioma cell proliferation, indicating the tumor suppresser role of miR-1321 in glioma.

What are known until now based on abovementioned studies include: (1) SERPINA1 is expressed in human glioma tissues; (2) NQO1 binds with SERPINA1 3′UTR in human hepatoma HepG2; and (3) NQO1 increases the proliferation of glioma cell lines. The novel findings of this study are listed as follows: (1) demonstrating the pro-proliferative and anti-apoptotic roles of SERPINA1 in both glioma cell lines and primary glioma cells as well as the same function of NQO1 in primary glioma cells; (2) confirming the binding of NQO1 and SERPINA1 3′UTR in glioma cells on the basis of a previous study showing their binding in another cancer cell line; (3) revealing that miR-1321 binds to SERPINA1 3′UTR to suppress SERPINA1 translation, indicating that NQO1 may compete with miR-1321 to enhance SERPINA1 expression; and (4) showing the antiproliferative function of miR-1321 in glioma cells.

In conclusion, our work demonstrates that in glioma cells, NQO1 enhances the translation of SERPINA1 mRNA by binding with 3′UTR and thus promotes the function of SERPINA1 by suppressing apoptosis and enhancing the proliferation. Moreover, miR-1321 is a negative regulator of SERPINA1. NQO1 may compete with miR-1321 to bind with SERPINA1 3′UTR and thus enhances its translation. This study suggested that NQO1 may have similar effects on other target mRNAs and brings novel solution of antitumor treatments for glioma in the future work.

Abbreviations

SERPINA1: serpin family A member 1
NQO1: nicotinamide adenine dinucleotide phosphate quinone oxidoreductase
mRNA: messenger RNA
shRNA: short hairpin RNA
SEM: standard error of the mean
GBM: glioblastoma multiforme
cDNA: complementary DNA
DAPI: 4′,6-diamidino-2-phenylindole
RBP: RNA-binding protein
RL: Renilla luciferase
FL: Firefly luciferase

# These authors contributed equally to this work.

Funding information: This work was supported by Wuhan Outstanding Young and middle-aged Medical Talents Fund.
Conflict of interest: The authors declare that there are no conflicts of interest in this study.
Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

[1] Bai QL, Hu CW, Wang XR, Shang JX, Yin GF. MiR-616 promotes proliferation and inhibits apoptosis in glioma cells by suppressing expression of SOX7 via the Wnt signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(24):5630–7.Suche in Google Scholar

[2] Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391–403.10.1016/j.ccr.2006.03.030Suche in Google Scholar PubMed

[3] Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005;65(19):8679–89.10.1158/0008-5472.CAN-05-1204Suche in Google Scholar PubMed

[4] Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209(3):507–20.10.1084/jem.20111424Suche in Google Scholar PubMed PubMed Central

[5] Barzon L, Zanusso M, Colombo F, Palù G. Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther. 2006;13(6):539–54.10.1038/sj.cgt.7700930Suche in Google Scholar PubMed

[6] Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2019;176(3):677.10.1016/j.cell.2019.01.008Suche in Google Scholar PubMed

[7] Scotté F, Ratta R, Beuzeboc P. Side effects of immunotherapy: a constant challenge for oncologists. Curr Opin Oncol. 2019;31(4):280–5.10.1097/CCO.0000000000000541Suche in Google Scholar PubMed

[8] Kurachi K, Chandra T, Degen SJ, White TT, Marchioro TL, Woo SL, et al. Cloning and sequence of cDNA coding for alpha 1-antitrypsin. Proc Natl Acad Sci U S A. 1981;78(11):6826–30.10.1073/pnas.78.11.6826Suche in Google Scholar PubMed PubMed Central

[9] Shin NR, Jeong EH, Choi CI, Moon HJ, Kwon CH, Chu IS, et al. Overexpression of snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. BMC Cancer. 2012;12:521.10.1186/1471-2407-12-521Suche in Google Scholar PubMed PubMed Central

[10] Kwon CH, Park HJ, Lee JR, Kim HK, Jeon TY, Jo HJ, et al. Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer. Br J Cancer. 2014;111(10):1993–2002.10.1038/bjc.2014.490Suche in Google Scholar PubMed PubMed Central

[11] Karashima S, Kataoka H, Itoh H, Maruyama R, Koono M. Prognostic significance of alpha-1-antitrypsin in early stage of colorectal carcinomas. Int J Cancer. 1990;45(2):244–50.10.1002/ijc.2910450207Suche in Google Scholar PubMed

[12] Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer. 1992;65(2):300–2.10.1038/bjc.1992.60Suche in Google Scholar

[13] Tahara E, Ito H, Taniyama K, Yokozaki H, Hata J. Alpha 1-antitrypsin, alpha 1-antichymotrypsin, and alpha 2-macroglobulin in human gastric carcinomas: a retrospective immunohistochemical study. Hum Pathol. 1984;15(10):957–64.10.1016/S0046-8177(84)80125-2Suche in Google Scholar

[14] Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK, Jo HJ, et al. Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget. 2015;6(24):20312–26.10.18632/oncotarget.3964Suche in Google Scholar PubMed PubMed Central

[15] Katoh M, Aida T, Sugimoto S, Suwamura Y, Abe H, Isu T, et al. Immunohistochemical analysis of giant cell glioblastoma. Pathol Int. 1995;45(4):275–82.10.1111/j.1440-1827.1995.tb03456.xSuche in Google Scholar PubMed

[16] Katsetos CD, Krishna L, Friedberg E, Reidy J, Karkavelas G, Savory J. Lobar pilocytic astrocytomas of the cerebral hemispheres: II. Pathobiology--morphogenesis of the eosinophilic granular bodies. Clin Neuropathol. 1994;13(6):306–14.Suche in Google Scholar

[17] Ookawa S, Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Ohtaki S, et al. Digital polymerase chain reaction quantification of SERPINA1 predicts prognosis in high-grade glioma. World Neurosurg. 2018;111:e783–e9.10.1016/j.wneu.2017.12.166Suche in Google Scholar PubMed

[18] Luo S, Lei K, Xiang D, Ye K. NQO1 is regulated by pten in glioblastoma, mediating cell proliferation and oxidative stress. Oxid Med Cell Longev. 2018;2018:9146528.10.1155/2018/9146528Suche in Google Scholar PubMed PubMed Central

[19] Lei K, Xia Y, Wang XC, Ahn EH, Jin L, Ye K. C/EBPβ mediates NQO1 and GSTP1 anti-oxidative reductases expression in glioblastoma, promoting brain tumor proliferation. Redox Biol. 2020;34:101578.10.1016/j.redox.2020.101578Suche in Google Scholar PubMed PubMed Central

[20] Di Francesco A, Di Germanio C, Panda AC, Huynh P, Peaden R, Navas-Enamorado I, et al. Novel RNA-binding activity of NQO1 promotes SERPINA1 mRNA translation. Free Radic Biol Med. 2016;99:225–33.10.1016/j.freeradbiomed.2016.08.005Suche in Google Scholar PubMed PubMed Central

[21] Chang L, Yin L, Zhang D, Wang C, Li G, Tan C, et al. MicroRNA-221 promotes tumor progression by targeting HHIP in human glioblastoma. Transl Cancer Res. 2021;10(2):1073–81.10.21037/tcr-21-99Suche in Google Scholar PubMed PubMed Central

[22] Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo Y, et al. LncRNA CASC2 interacts with miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway. J Cell Biochem. 2017;118(7):1889–99.10.1002/jcb.25910Suche in Google Scholar PubMed

[23] Zhang H, Wei DL, Wan L, Yan SF, Sun YH. Highly expressed lncRNA CCND2-AS1 promotes glioma cell proliferation through Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2017;482(4):1219–25.10.1016/j.bbrc.2016.12.016Suche in Google Scholar

[24] Mullins DE, Rohrlich ST. The role of proteinases in cellular invasiveness. Biochim Biophys Acta. 1983;695(3–4):177–214.10.1016/0304-419X(83)90011-2Suche in Google Scholar

[25] Breit SN, Wakefield D, Robinson JP, Luckhurst E, Clark P, Penny R. The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin Immunol Immunopathol. 1985;35(3):363–80.10.1016/0090-1229(85)90097-2Suche in Google Scholar

[26] Redelman D, Hudig D. The mechanism of cell-mediated cytotoxicity. I. killing by murine cytotoxic T lymphocytes requires cell surface thiols and activated proteases. J Immunol. 1980;124(2):870–8.10.4049/jimmunol.124.2.870Suche in Google Scholar

[27] Ades EW, Hinson A, Chapuis-Cellier C, Arnaud P. Modulation of the immune response by plasma protease inhibitors. I. Alpha 2-macroglobulin and alpha 1-antitrypsin inhibit natural killing and antibody-dependent cell-mediated cytotoxicity. Scand J Immunol. 1982;15(1):109–13.10.1111/j.1365-3083.1982.tb00628.xSuche in Google Scholar PubMed

[28] Ashton-Rickardt PG. An emerging role for serine protease inhibitors in T lymphocyte immunity and beyond. Immunol Lett. 2013;152(1):65–76.10.1016/j.imlet.2013.04.004Suche in Google Scholar PubMed

[29] Sawaya R, Mandybur T, Ormsby I, Tew JMJr. Antifibrinolytic therapy of experimentally grown malignant brain tumors. J Neurosurg. 1986;64(2):263–8.10.3171/jns.1986.64.2.0263Suche in Google Scholar PubMed

[30] Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749–57.10.1056/NEJMcp0900449Suche in Google Scholar PubMed

[31] Hunt JM, Tuder R. Alpha 1 anti-trypsin: one protein, many functions. Curr Mol Med. 2012;12(7):827–35.10.2174/156652412801318755Suche in Google Scholar PubMed

Received: 2022-03-17

Revised: 2022-08-29

Accepted: 2022-08-29

Published Online: 2022-10-20

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

https://doi.org/10.1515/med-2022-0572

Schlagwörter für diesen Artikel

glioma; SERPINA1; NQO1; RNA-binding protein; miR-1321

Creative Commons

BY 4.0